Octagon Capital Advisors LP Unicycive Therapeutics, Inc. Transaction History
Octagon Capital Advisors LP
- $449 Million
- Q4 2024
A detailed history of Octagon Capital Advisors LP transactions in Unicycive Therapeutics, Inc. stock. As of the latest transaction made, Octagon Capital Advisors LP holds 10,000,000 shares of UNCY stock, worth $6.8 Million. This represents 1.76% of its overall portfolio holdings.
Number of Shares
10,000,000
Previous 8,559,000
16.84%
Holding current value
$6.8 Million
Previous $3.51 Million
125.14%
% of portfolio
1.76%
Previous 0.85%
Shares
2 transactions
Others Institutions Holding UNCY
# of Institutions
32Shares Held
61.7MCall Options Held
0Put Options Held
0-
Great Point Partners LLC Greenwich, CT11MShares$7.47 Million5.72% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT10.4MShares$7.07 Million0.41% of portfolio
-
Vivo Capital, LLC Palo Alto, CA9.97MShares$6.78 Million1.54% of portfolio
-
Logos Global Management LP San Francisco, CA5.08MShares$3.45 Million0.53% of portfolio
-
Walleye Capital LLC Plymouth, MN5MShares$3.4 Million0.01% of portfolio
About Unicycive Therapeutics, Inc.
- Ticker UNCY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,052,500
- Market Cap $10.2M
- Description
- Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...